Erratum: Immunologic consequences of francisella tularensis live vaccine strain infection: Role of the innate immune response in infection and immunity (Journal of Immunology (2006) 176 (6888-6899) DOI: 10.4049/jimmunol.176.11.6888);Immunologic consequences of Francisella tularensis live vaccine strain infection: Role of the innate immune response in infection and immunity

Journal of Immunology

Volumn 176, Issue 11, 2006, Pages 6888-6899

  Cole, Leah E ^a   Elkins, Karen L ^b   Michalek, Suzanne M ^c   Qureshi, Nilofer ^d   Eaton, Linda J ^e   Rallabhandi, Prasad ^a   Cuesta, Natalia ^a   Vogel, Stefanie N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^e List Biological Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD14 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN M ANTIBODY; LIPOPOLYSACCHARIDE; LIVE VACCINE; MESSENGER RNA; PROTEIN MD 2; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; CELL STRAIN HEK293; CONTROLLED STUDY; FRANCISELLA TULARENSIS; GENE EXPRESSION; GRAM NEGATIVE INFECTION; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; LETHAL DOSE; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TULAREMIA;

EID: 33646881570     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.2100505     Document Type: Erratum

References (72)

1. Tarnvik, A. 1989. Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis. 11: 440-451.
2. Ellis, J., P. C. Oyston, M. Green, and R. W. Titball. 2002. Tularemia. Clin. Microbiol. Rev. 15: 631-646.
3. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, et al. 2001. Tularemia as a biological weapon: medical and public health management. J. Am. Med. Assoc. 285: 2763-2773.
4. Centers for Disease Control and Prevention. 2002. Tularemia-United States, 1990-2000. Morb. Mortal. Wkly. Rep. 51: 181-184.
5. Oyston, P. C., A. Sjostedt, and R. W. Titball. 2004. Tularaemia: bioterrorism defense renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2: 967-978.
6. Elkins, K. L., S. C. Cowley, and C. M. Bosio. 2003. Innate and adaptive immune responses to an intracellular bacterium: Francisella tularensis live vaccine strain. Microbes. Infect. 5: 135-142.
7. Eigelsbach, H. T., and C. M. Downs. 1961. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J. Immunol. 87: 415-425.
8. Saslaw, S., H. T. Eigelsbach, H. E. Wilson, J. A. Prior, and S. Carhart. 1961. Tularemia vaccine study. I. Intracutaneous challenge. Arch. Intern. Med. 107: 689-701.
9. Saslaw, S., H. T. Eigelsbach, J. A. Prior, H. E. Wilson, and S. Carhart. 1961. Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107: 702-714.
10. Fortier, A. H., M. V. Slayter, R. Ziemba, M. S. Meltzer, and C. A. Nacy. 1991. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect. Immun. 59: 2922-2928.
11. Green, M., G. Choules, D. Rogers, and R. W. Titball. 2005. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease. Vaccine 23: 2680-2686.
12. Elkins, K. L., R. K. Winegar, C. A. Nacy, and A. H. Fortier. 1992. Introduction of Francisella tularensis at skin sites induces resistance to infection and generation of protective immunity. Microb. Pathog. 13: 417-421.
13. Elkins, K. L., T. Rhinehart-Jones, C. A. Nacy, R. K. Winegar, and A. H. Fortier. 1993. T-cell-independent resistance to infection and generation of immunity to Francisella tularensis. Infect. Immun. 61: 823-829.
14. Stenmark, S., D. Sunnemark, A. Bucht, and A. Sjostedt. 1999. Rapid local expression of interleukin-12, tumor necrosis factor α, and γ interferon after cutaneous Francisella tularensis infection in tularemia-immune mice. Infect. Immun. 67: 1789-1797.
15. Forestal, C. A., J. L. Benach, C. Carbonara, J. K. Italo, T. J. Lisinski, and M. B. Furie. 2003. Francisella tularensis selectively induces proinflammatory changes in endothelial cells. J. Immunol. 171: 2563-2570.
16. Golovliov, I., G. Sandstrom, M. Ericsson, A. Sjostedt, and A. Tarnvik. 1995. Cytokine expression in the liver during the early phase of murine tularemia. Infect. Immun. 63: 534-538.
17. Golovliov, I., K. Kuoppa, A. Sjostedt, A. Tamvik, and G. Sandstrom. 1996. Cytokine expression in the liver of mice infected with a highly virulent strain of Francisella tularensis. FEMS Immunol. Med. Microbiol. 13: 239-244.
18. Foitier, A. H., S. J. Green, T. Polsinelli, T. R. Jones, R. M. Crawford, D. A. Leiby, K. L. Elkins, M. S. Meltzer, and C. A. Nacy. 1994. Life and death of an intracellular pathogen: Francisella tularensis and the macrophage. Immunol. Ser. 60: 349-361.
19. Ancuta, P., T. Pedron, R. Girard, G. Sandstrom, and R. Chaby. 1996. Inability of the Francisella tularensis lipopolysaccharide to mimic or to antagonize the induction of cell activation by endotoxins. Infect. Immun. 64: 2041-2046.
20. Sandstrom, G., A. Sjostedt, T. Johansson, K. Kuoppa, and J. C. Williams. 1992. Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS. FEMS Microbiol. Immunol. 5: 201-210.
21. Dreisbach, V. C., S. Cowley, and K. L. Elkins. 2000. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and γ interferon. Infect. Immun. 68: 1988-1996.
22. Phillips, N. J., B. Schilling, M. K. McLendon, M. A. Apicella, and B. W. Gibson. 2004. Novel modification of lipid A of Francisella tularensis. Infect. Immun. 72: 5340-5348.
23. Vinogradov, E., M. B. Perry, and J. W. Conlan. 2002. Structural analysis of Francisella tularensis lipopolysaccharide. Eur. J. Biochem. 269: 6112-6118.
24. Loppnow, H., H. Brade, I. Durrbaum, C. A. Dinarello, S. Kusumoto, E. T. Rietschel, and H. D. Flad. 1989. IL-1 induction-capacity of defined lipopolysaccharide partial structures. J. Immunol. 142: 3229-3238.
25. Fulop, M., R. Manchee, and R. Titball. 1995. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 13: 1220-1225.
26. Fulop, M., P. Mastroeni, M. Green, and R. W. Titball. 2001. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19: 4465-4472.
27. Rhinehart-Jones, T. R., A. H. Fortier, and K. L. Elkins. 1994. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host γ interferon and T cells. Infect. Immun. 62: 3129-3137.
28. Salkowski, C. A., K. Kopydlowski, J. Blanco, M. J. Cody, R. McNally, and S. N. Vogel. 1999. IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice. J. Immunol. 163: 1529-1536.
29. McIntire, F. C., H. W. Sievert, G. H. Barlow, R. A. Finley, and A. Y. Lee. 1967. Chemical, physical, biological properties of a lipopolysaccharide from Escherichia coli K-235. Biochemistry 6: 2363-2372.
30. Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides. In Methods in Carbohydrate Chemistry. R. L. Whistler, ed. Academic Press, New York, pp. 83-91.
31. Manthey, C., and S. N. Vogel. 1994. Elimination of trace endotoxin protein from rough chemotype LPS. J. Endotoxin Res. 1: 84-91.
32. Cuesta, N., C. A. Salkowski, K. E. Thomas, and S. N. Vogel. 2003. Regulation of lipopolysaccharide sensitivity by IFN regulatory factor-2. J. Immunol. 170: 5739-5747.
33. Azam, P., J. L. Peiffer, J. C. Ourlin, P. A. Bonnet, M. H. Tissier, L. Vian, and I. Fahre. 2005. Qualitative and quantitative evaluation of a local lymph node assay based on ex vivo interleukin-2 production. Toxicology 206: 285-298.
34. Medvedev, A. E., and S. N. Vogel. 2003. Overexpression of CD14, TLR4, and MD-2 in HEK 293T cells does not prevent induction of in vitro endotoxin tolerance. J. Endotoxin Res. 9: 60-64.
35. Miller, S. I., R. K. Ernst, and M. W. Bader. 2005. LPS, TLR4 and infectious disease diversity. Nat. Rev. Microbiol. 3: 36-46.
36. Miyake, K. 2004. Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol. 12: 186-192.
37. Beutler, B., K. Hoebe, X. Du, and R. J. Ulevitch. 2003. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J. Leukocyte Biol. 74: 479-485.
38. Hirschfeld, M., J. J. Weis, V. Toshchakov, C. A. Salkowski, M. J. Cody, D. C. Ward, N. Qureshi, S. M. Michalek, and S. N. Vogel. 2001. Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun. 69: 1477-1482.
39. Werts, C., R. I. Tapping, J. C. Mathison, T. H. Chuang, V. Kravchenko, I. Saint Girons, D. A. Haake, P. J. Godowski, F. Hayashi, A. Ozinsky, et al. 2001. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat. Immunol. 2: 346-352.
40. Erridge, C., J. Stewart, E. Bennett-Guerrero, T. J. McIntosh, and I. R. Poxton. 2002. The biological activity of a liposomal complete core lipopolysaccharide vaccine. J. Endotoxin Res. 8: 39-46.
41. Netea, M. G., M. van Deuren, B. J. Kullberg, J. M. Cavaillon, and J. W. Van der Meer. 2002. Does the shape of lipid A determine the interaction of LPS with Toll-like receptors? Trends Immunol. 23: 135-139.
42. Takayama, K., N. Qureshi, B. Beutler, and T. N. Kirkland. 1989. Diphosphoryl lipid A from Rhodopseudomonas sphaeroides ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide. Infect. Immun. 57: 1336-1338.
43. Henricson, B. E., P. Y. Perera, N. Qureshi, K. Takayama, and S. N. Vogel. 1992. Rhodopseudomonas sphaeroides lipid A derivatives block in vitro induction of tumor necrosis factor and endotoxin tolerance by smooth lipopolysaccharide and monophosphoryl lipid A. Infect. Immun. 60: 4285-4290.
44. Kovach, N. L., E. Yee, R. S. Munford, C. R. Raetz, and J. M. Harlan. 1990. Lipid IVA inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo. J. Exp. Med. 172: 77-84.
45. Dobrovolskaia, M. A., A. E. Medvedev, K. E. Thomas, N. Cuesta, V. Toshchakov, T. Ren, M. J. Cody, S. M. Michalek, N. R. Rice, and S. N. Vogel. 2003. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-κB signaling pathway components. J. Immunol. 170: 508-519.
46. Golovliov, I., V. Baranov, Z. Krocova, H. Kovarova, and A. Sjostedt. 2003. An attenuated strain of the facultative intracellular bacterium Francisella tularensis can escape the phagosome of monocytic cells. Infect. Immun. 71: 5940-5950.
47. Lindgren, H., I. Golovliov, V. Baranov, R. K. Ernst, M. Telepnev, and A. Sjostedt. 2004. Factors affecting the escape of Francisella tularensis from the phagolysosome. J. Med. Microbiol. 53: 953-958.
48. Telepnev, M., I. Golovliov, and A. Sjostedt. 2005. Francisella tularensis LVS initially activates but subsequently down-regulates intracellular signaling and cytokine secretion in mouse monocytic and human peripheral blood mononuclear cells. Microb. Pathog. 38: 239-247.
49. Santic, M., M. Molmeret, K. E. Klose, S. Jones, and Y. A. Kwaik. 2005. The Francisella tularensis pathogenicity island protein IgIC and its regulator MgIA are essential for modulating phagosome biogenesis and subsequent bacterial escape into the cytoplasm. Cell Microbiol. 7: 969-979.
50. Lai, X. H., I. Golovliov, and A. Sjostedt. 2004. Expression of IgIC is necessary for intracellular growth and induction of apoptosis in murine macrophages by Francisella tularensis. Microb. Pathog. 37: 225-230.
51. Anthony, L. S., and P. A. Kongshavn. 1987. Experimental murine tularemia caused by Francisella tularensis, live vaccine strain: a model of acquired cellular resistance. Microb. Pathog. 2: 3-14.
52. Collazo, C. M., A. Sher, A. I. Meierovics, and K. L. Elkins. 2005. Myeloid differentiation factor-88 (MyD88) is essential for control of primary in vivo Francisella tularensis LVS infection, but not for control of intramacrophage bacterial replication. Microbes. Infect. In press.
53. Elkins, K. L., T. R. Rhinehart-Jones, S. J. Culkin, D. Yee, and R. K. Winegar. 1996. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect. Immun. 64: 3288-3293.
54. Anthony, L. S., E. Ghadirian, F. P. Nestel, and P. A. Kongshavn. 1989. The requirement for γ interferon in resistance of mice to experimental tularemia. Microb. Pathog. 7: 421-428.
55. Fortier, A. H., T. Polsinelli, S. J. Green, and C. A. Nacy. 1992. Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect. Immun. 60: 817-825.
56. Leiby, D. A., A. H. Fortier, R. M. Crawford, R. D. Schreiber, and C. A. Nacy. 1992. In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect. Immun. 60: 84-89.
57. Culkin, S. J., T. Rhinehart-Jones, and K. L. Elkins. 1997. A novel role for B cells in early protective immunity to an intracellular pathogen. Francisella tularensis strain LVS. J. Immunol. 158: 3277-3284.
58. Lindgren, H., S. Stenmark, W. Chen, A. Tamvik, and A. Sjostedt. 2004. Distinct roles of reactive nitrogen and oxygen species to control infection with the facultative intracellular bacterium Francisella tularensis. Infect. Immun. 72: 7172-7182.
59. Sjostedt, A., J. W. Conlan, and R. J. North. 1994. Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect. Immun. 62: 2779-2783.
60. Conlan, J. W., R. Kuolee, H. Shen, and A. Webb. 2002. Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen: Francisella tularensis LVS. Microb. Pathog. 32: 127-134.
61. Kovach, N. L., E. Yee, R. S. Munford, C. R. Raetz, and J. M. Harlan. 1990. Lipid IVA inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo. J. Exp. Med. 172: 77-84.
62. Chen, W., R. Kuolee, H. Shen, M. Busa, and J. W. Conlan. 2004. Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A Francisella tularensis. Microb. Pathog. 37: 185-191.
63. Hirschfeld, M., C. J. Kirschning, R. Schwandner, H. Wesche, J. H. Weis, R. M. Wooten, and J. J. Weis. 1999. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by Toll-like receptor 2. J. Immunol. 163: 2382-2386.
64. Lien, E., T. J. Sellati, A. Yoshimura, T. H. Flo, G. Rawadi, R. W. Finberg, J. D. Carroll, T. Espevik, R. R. Ingalls, J. D. Radolf, and D. T. Golenbock. 1999. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem. 274: 33419-33425.
65. Yoshimura, A., E. Lien, R. R. Ingalls, E. Tuomanen, R. Dziarski, and D. Golenbock. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163: 1-5.
66. Mizel, S. B., A. N. Honko, M. A. Moors, P. S. Smith, and A. P. West. 2003. Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes. J. Immunol. 170: 6217-6223.
67. Abplanalp, A., B. Panda, J. Teale, and M. Berton. 2005. Toll-like receptor signaling and the immune response to pulmonary F. tularensis infection in the mouse. Tularemia Workshop (Abstr.).
68. Conlan, J. W., H. Shen, A. Webb, and M. B. Perry. 2002. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20: 3465-3471.
69. Vinogradov, E. V., A. S. Shashkov, Y. A. Knirel, N. K. Kochetkov, N. V. Tochtamysheva, S. F. Averin, O. V. Goncharova, and V. S. Khlebnikov. 1991. Structure of the O-antigen of Francisella tularensis strain 15. Carbohydr. Res. 214: 289-297.
70. Prior, J. L., R. G. Prior, P. G. Hitchen, H. Diaper, K. F. Griffin, H. R. Morris, A. Dell, and R. W. Titball. 2003. Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. J. Med. Microbiol. 52: 845-851.
71. Conlan, J. W., E. Vinogradov, M. A. Monteiro, and M. B. Perry. 2003. Mice intradermally-inoculated with the intact lipopolysaccharide, but not the lipid A or O-chain, from Francisella tularensis LVS rapidly acquire varying degrees of enhanced resistance against systemic or aerogenic challenge with virulent strains of the pathogen. Microb. Pathog. 34: 39-45.
72. Katz, J., P. Zhang, M. Martin, S. N. Vogel, and S. M. Michalek. 2006. Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect. Immun. In press.